Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with a specific reporting date of July 8, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details transactions executed on July 5, 2022, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Instrument | Transaction Price | Total Volume (Shares/ADSs) | Exchange |
|---|---|---|---|
| Ordinary Shares (GBP) | £17.8560 | 3,681 | London Stock Exchange |
| American Depositary Shares (USD) | $43.7500 | 1,089 | New York Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position or operations. The reported activity consists of an increase in notional interest in shares for various executives. These increases resulted from the automatic re-investment of dividends paid to shareholders on July 1, 2022, into the Company's Deferred Annual Bonus Plan. No open market purchases or sales by executives are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a statutory disclosure of specific shareholding changes required by securities regulations.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic dividend re-investments into the Deferred Annual Bonus Plan, not discretionary trades.
- Participants: Transactions involved 14 senior executives, including the CEO (Ms E Walmsley), CFO (Mr I Mackay), and CSO (Dr H Barron).
- Share Prices: Ordinary Shares traded at £17.8560 and ADSs traded at $43.7500 on the transaction date of July 5, 2022.
- Scope: This filing does not provide data on GSK's overall financial performance for the period; investors should refer to Form 20-F or quarterly earnings releases for that information.